Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

CBER Director Midthun Retiring; Legacy Includes Biosimilar Principles, Avastin Withdrawal

This article was originally published in The Pink Sheet Daily

Executive Summary

While CBER is often perceived to be as much focused on research as it is on application review, Midthun was central to many key policy debates.


Related Content

Woodcock's Legacy: CDER Organizational Improvements
CBER Approvals Hit A High Note For Director Midthun's Swan Song
People In The News: CEO Post Changes Hands At Express Scripts, Xenoport, Promethera, Molecular Response, Protagonist
CDER Pharmaceutical Quality Office Gains Permanent Director
FDA’s Acting Chief Scientist Offers Vaccine Continuity As Goodman Departs
CDER’s Woodcock Retiring? Rumors Never Go On Furlough
FDA Grants Hearing To Appeal Avastin Breast Cancer Withdrawal
Follow-On Biologics' Bumpy Pathway: Was The CBO Savings Score Too High?
FDA’s Goodman Moving Up: Named Acting Chief Medical Officer, Appointed To CER Panel


Related Companies